Leanne F Harris
Overview
Explore the profile of Leanne F Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jigar Panchal H, Kent N, Knox A, Harris L
Molecules
. 2020 Feb;
25(4).
PMID: 32075008
Haemostatic disorders are both complex and costly in relation to both their treatment and subsequent management. As leading causes of mortality worldwide, there is an ever-increasing drive to improve the...
2.
Harris L, Rainey P, Castro-Lopez V, ODonnell J, Killard A
Analyst
. 2013 May;
138(17):4769-76.
PMID: 23666610
The development of new point of care coagulation assay devices is necessary due to the increasing number of patients requiring long-term anticoagulation in addition to the desire for appropriate, targeted...
3.
Gubala V, Harris L, Ricco A, Tan M, Williams D
Anal Chem
. 2012 Jan;
84(2):487-515.
PMID: 22221172
No abstract available.
4.
Castro-Lopez V, Murray B, Harris L, ODonnell J, Killard A
Blood Coagul Fibrinolysis
. 2011 Nov;
23(1):98-103.
PMID: 22089943
Four commercially available factor Xa (FXa) reagents were evaluated in a fluorogenic anti-FXa assay. The four reagents - of which three were of human origin and the fourth was bovine...
5.
Harris L, OBrien A, Castro-Lopez V, ODonnell J, Killard A
Thromb Res
. 2011 Aug;
128(6):e166-70.
PMID: 21872908
Introduction: Fast and accurate monitoring is crucial in the successful regulation of coagulation therapy. For the treatment of venous thromboembolism, both unfractionated heparin (UFH) and low molecular weight heparins (LMWHs)...
6.
Castro-Lopez V, Harris L, ODonnell J, Killard A
J Pharm Biomed Anal
. 2011 Aug;
56(5):992-7.
PMID: 21852056
Novel and sensitive plate-based fluorogenic anti-factor Xa (FXa) assays were investigated to quantify unfractionated heparin (UFH) in human plasma and whole blood within the therapeutic ranges of 0-1.6 U/mL and...
7.
Harris L, Castro-Lopez V, Jenkins P, ODonnell J, Killard A
Thromb Res
. 2011 Aug;
128(6):e125-9.
PMID: 21824646
Introduction: Low molecular weight heparins (LMWHs) are used worldwide for the treatment and prophylaxis of thromboembolic disorders. Routine laboratory tests are not required due to the predictable pharmacokinetics of LMWHs,...
8.
Castro-Lopez V, Harris L, ODonnell J, Killard A
Anal Bioanal Chem
. 2010 Oct;
399(2):691-700.
PMID: 20972772
Low molecular weight heparins (LMWHs) are recognised as the preferred anticoagulants in the prevention and treatment of venous thromboembolism. Anti-Factor Xa (anti-FXa) levels are used to monitor the anticoagulant effect...
9.
Harris L, Castro-Lopez V, Hammadi N, ODonnell J, Killard A
Talanta
. 2010 May;
81(4-5):1725-30.
PMID: 20441964
Fluorogenic assays have many potential advantages over traditional clot-based and chromogenic assays such as the absence of interference from a range of factor deficiencies as well as offering the possibility...